Size, Share & Industry Analysis, By Modality (MRI Devices, CT Devices, PET Devices, Hybrid PET/CT and PET/MR Devices), By Clinical Application (Neurological Disease Diagnosis, Stroke and Trauma, Brain Oncology, Neuroscience Research), By Purchasing Setting (Hospitals, Independent Imaging Centers, Academic and Specialty Centers), By Imaging Purpose (Structural Imaging, Functional Imaging, Molecular Imaging), and Regional Forecast, 2026-2034
Explore the report section by section.
The global Brain Imaging Devices Market was valued at USD 11.6 billion in 2025, is estimated at USD 12.3 billion in 2026, and is projected to reach USD 19.7 billion by 2034, reflecting a 6.1% CAGR over 2026–2034.
Brain imaging equipment includes magnetic resonance imaging, computed tomography, positron emission tomography and combined PET/CT or PET/MR scanners used to visualize the human brain. The revenue boundary is the brain-use-attributable share of finished scanner hardware, dedicated acquisition upgrades and bundled installation support. It excludes payments for individual scans, radiologist interpretation, contrast agents, radiotracers, unrelated body-imaging usage and independently sold image-analysis subscriptions. A multipurpose hospital MRI is counted only to the extent that its installed capacity serves neuroimaging.
The World Health Organization reported in October 2025 that neurological conditions affect more than 3 billion people and contribute to over 11 million deaths each year. Stroke, dementia, epilepsy and brain tumors require different acquisition protocols, creating parallel demand for emergency CT, detailed MRI and selected molecular imaging. Demand does not convert automatically into scanner sales because lower-income health systems face staffing, capital-budget and maintenance constraints. Public purchasing programs and faster imaging workflows can therefore affect equipment revenue more directly than disease prevalence alone.
MRI manufacturers are changing acquisition economics through faster sequences and new magnet designs cleared during 2025–2026. GE HealthCare announced FDA clearances for SIGNA Sprint with Freelium and SIGNA Bolt in February 2026, while Siemens Healthineers obtained U.S. clearance for its 1.5T Magnetom Flow.Ace in June 2025. Philips reported that SmartSpeed Precise software was cleared in July 2025 for compatible 1.5T and 3T MRI systems. These advances target scanner throughput, helium dependency and reconstruction time, helping institutions justify upgrades when clinical demand exceeds available appointment slots.
Portable brain MRI devices such as Hyperfine Swoop are extending selected neurological imaging workflows beyond conventional radiology suites. Hyperfine began a European launch of its next-generation Swoop portable brain MRI in July 2026 after CE and UKCA clearance, while United Imaging announced CE marking for uPMR Zenith PET/MR in September 2026. Such products address different clinical needs: portable low-field MRI reduces transport for selected patients, whereas PET/MR combines molecular and structural information in specialist centers. Their prices, indications and installation requirements prevent treating them as interchangeable scanners.
Source: World Health Organization; NHS England; GE HealthCare; Hyperfine.
The scope measures the neuroimaging-use portion of clinical scanner sales and dedicated equipment upgrades, classified once by acquisition modality, primary indication, buyer setting and imaging purpose.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Modality | MRI Devices; CT Devices; PET Devices; Hybrid PET/CT and PET/MR Devices |
| By Clinical Application | Neurological Disease Diagnosis; Stroke and Trauma; Brain Oncology; Neuroscience Research |
| By Purchasing Setting | Hospitals; Independent Imaging Centers; Academic and Specialty Centers |
| By Imaging Purpose | Structural Imaging; Functional Imaging; Molecular Imaging |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; United Kingdom; China; Japan; India; Brazil; Mexico; Saudi Arabia; United Arab Emirates |
| Key Market Players | GE HealthCare Technologies Inc.; Siemens Healthineers AG; Koninklijke Philips N.V.; Canon Medical Systems Corporation; FUJIFILM Holdings Corporation; Hyperfine Inc.; United Imaging Healthcare Co., Ltd.; Neusoft Medical Systems Co., Ltd.; MinFound Medical Systems Co., Ltd.; Samsung NeuroLogica Corporation |
The market counts the brain-use allocation of multipurpose clinical MRI, CT and PET scanners, including hybrid systems, plus dedicated portable head imaging equipment and integrated acquisition software supplied with those devices. A general radiology scanner serving brain and nonbrain examinations contributes only its neuroimaging portion. Imaging-center fees, physician billing, injected radiopharmaceuticals, separate PACS subscriptions and consumer or veterinary equipment do not enter equipment revenue.
Each scanner sale belongs to exactly one modality group; PET/MR and PET/CT systems are classified as hybrid rather than counted again under standalone PET, MRI or CT. Clinical application is the principal procurement rationale, not every diagnosis that a device could support. Neuroscience research refers to human clinical and translational installations, excluding preclinical animal-only instruments. Service contracts are included only when directly bundled into recognized device revenue.
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Neurological disease burden and hospital demand for MRI and CT | High | +2.20% | High | High | High |
| AI reconstruction and faster neuroimaging examination throughput | High | +1.80% | High | High | Medium |
| Public scanner procurement in underserved health systems | Medium-High | +1.40% | High | High | Medium |
| Portable MRI expansion into intensive care and neurology | Medium | +1.10% | Medium | High | High |
| Hybrid PET/MR and biomarker-driven imaging adoption | Low-Medium | +0.90% | Medium | Medium | High |
| Others (equipment replacement, service access, research upgrades) | Low | +0.60% | Medium | Medium | Medium |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Scanner capital budgets and installation complexity | High | -0.90% | High | High | Medium |
| Radiology workforce shortages and maintenance constraints | Medium-High | -0.60% | High | Medium | Medium |
| PET tracer logistics and uneven reimbursement | Medium | -0.30% | Medium | Medium | Low |
| Others (regulatory delays, energy costs, procurement cycles) | Low | -0.10% | Low | Low | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 6.1% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
WHO documented more than 3 billion people affected by neurological conditions in its October 2025 global status report, including major burdens from stroke and dementia. Emergency departments need rapid CT for hemorrhage assessment, while neurologists use MRI to characterize lesions, tumors and structural change. The coexistence of urgent and longitudinal pathways supports several scanner configurations within larger hospitals. Equipment orders still depend on funded budgets, available technologists and installation readiness; disease burden alone is not a direct measure of manufacturer sales.
Philips received FDA 510(k) clearance for SmartSpeed Precise in July 2025 and reported scan acceleration of up to threefold in supported workflows. GE HealthCare followed with clearance for SIGNA One and two scanner platforms in February 2026. Shorter protocols can allow more examinations per installed scanner, strengthening replacement economics where queues are long. Vendors that offer compatible upgrades may capture software-inclusive hardware orders, although throughput gains can also postpone purchases of additional machines in hospitals with spare capacity.
Hyperfine began European commercialization of its next-generation Swoop portable MRI system in July 2026 following CE and UKCA approvals. The device can support selected bedside brain examinations when transporting critically ill patients to fixed MRI suites is difficult. Portable systems address a narrower diagnostic range than high-field scanners and should not be treated as direct substitutes for every neurological indication. Their commercial opportunity depends on clinical protocols, operator training and whether hospitals value transport avoidance enough to fund an additional device.
High-field MRI installation can require structural preparation, radiofrequency shielding, electrical upgrades and specialist maintenance, while PET additionally relies on radiopharmaceutical logistics. Siemens Healthineers described its Magnetom Flow platform as using 0.7 liters of helium, compared with up to 1,500 liters in conventional designs, to reduce siting and operating complexity. These improvements do not eliminate procurement barriers where facilities lack radiographers or reliable service networks. Government tenders and leasing arrangements remain central to adoption in smaller cities.
Brazil planned a 2025 consultation for 40 CT and 40 MRI units under its PAC +Imagem program, while Mexico announced the acquisition of 17 advanced MRI scanners in June 2026. Such programs translate diagnostic capacity objectives into identifiable equipment tenders, although the stated procurement volumes cover whole-body imaging and are not equivalent to brain-only sales. The market captures only the neuroimaging-use portion of each purchased multipurpose scanner. Staffing shortages, reimbursement rules and delayed site preparation can shift the timing of revenue recognition even after funding is announced.
Sources: WHO global neurology status report; Philips FDA clearance announcement; GE HealthCare; Hyperfine; Siemens Healthineers; Brazil Ministry of Health; Mexican IMSS.
Siemens Healthineers obtained FDA clearance for Magnetom Flow.Ace in June 2025, describing a closed helium circuit without a quench pipe. Fujifilm announced its ECHELON Synergy ZeroHelium model in Japan in April 2025, with commercial introduction scheduled for June. Philips unveiled a helium-free 3.0T BlueSeal Horizon platform in November 2025, while product availability remains subject to market-specific clearances. Lower cooling and building requirements can widen MRI placement options, particularly where hospitals cannot support traditional helium infrastructure. The effect is strongest for replacement decisions involving older magnets.
GE HealthCare announced FDA clearance for SIGNA One in February 2026 alongside SIGNA Bolt and Sprint hardware. Philips cleared SmartSpeed Precise in July 2025 for compatible MRI systems, using reconstruction to improve image quality and speed. Such integrated features influence hardware selection because radiology managers evaluate examination time, patient movement and repeat scans. Independent image-analysis subscriptions remain outside the device revenue boundary unless supplied as part of the scanner transaction. Compatibility with an existing installed base can support upgrades without immediate full replacement.
United Imaging reported CE marking for its uPMR Zenith PET/MR platform on 29 September 2026, expanding access to simultaneous molecular and structural acquisition in Europe. Hybrid systems can support selected dementia research and brain tumor assessment when functional information adds value to MRI anatomy. These installations require specialized interpretation, tracer supply and investment beyond a standard scanner. Their revenue share is therefore smaller than routine MRI and CT, although a premium capital price and academic procurement can support higher equipment value per installation.
Hyperfine received another FDA clearance for Optive AI software on 20 August 2026, adding improved Swoop image quality and an isotropic sequence. The company had already begun a European commercial launch in July following CE and UKCA clearances. Bedside imaging may reduce patient transport from intensive care and make serial assessment more practical in facilities with limited MRI access. Ultra-low-field equipment has different resolution and protocol capabilities from 1.5T or 3T scanners, so procurement is complementary rather than universal replacement.
England recorded 49.6 million diagnostic imaging tests in the twelve months to March 2025, and its statistical series documents CT and MRI activity by provider. In June 2026, Mexico reported 17 newly acquired MRI systems, including eleven 1.5T and six 3T units. Brazil published specifications for planned CT and MRI acquisitions in July 2025. Public buyers increasingly compare patient throughput, siting requirements, staffing and maintenance obligations rather than purchase price alone. Neuroimaging demand receives only a share of these general radiology investments.
MRI, CT, PET and hybrid devices are assigned by the physical acquisition platform purchased. A combined PET/CT or PET/MR scanner appears only in the hybrid category, even when clinicians use both data streams for one brain examination. Assigning a scanner to one acquisition category prevents duplicate equipment revenue across modalities.
MRI Devices represented an estimated ~48% of 2025 revenue. High-field scanners support epilepsy protocols, brain tumor planning, dementia assessment and white-matter imaging. GE HealthCare cleared SIGNA Bolt and Sprint platforms in February 2026, and Siemens obtained U.S. clearance for Flow.Ace in 2025. MRI installations require shielding, trained personnel and quality-control programs. Only brain-use-attributable hardware revenue is included for multipurpose hospital scanners.
CT scanners provide fast cross-sectional brain imaging for stroke, head trauma and acute hemorrhage assessment. Canon Medical introduced an Alphenix 4D CT hybrid system in November 2025, while Neusoft Medical markets CT platforms with brain perfusion capability. CT equipment has broad emergency demand and shorter examinations than conventional MRI. Revenue is allocated by neuroimaging use rather than every body examination performed on the same machine. Large installed CT fleets support replacement demand.
Standalone PET systems support selected brain metabolism and biomarker studies, particularly at specialist academic centers. Their use is constrained by tracer availability, specialist interpretation and radiation exposure considerations. Radiopharmaceutical doses and billed scans are excluded from PET equipment revenue. A hospital purchasing an integrated PET/CT unit is recorded under the hybrid group, not this standalone category.
Hybrid scanners combine anatomical and molecular information within one capital asset. United Imaging announced CE marking for uPMR Zenith PET/MR in September 2026, while its digital PET/CT portfolio is used in European imaging centers. Their brain-use share is counted once when the same scanner also serves oncology and other indications.
MRI is expected to remain the largest modality by revenue, while CT maintains indispensable emergency demand. Portable low-field MRI and hybrid PET/MR introduce distinct installation options without eliminating the clinical need for fixed high-field equipment.
The principal clinical reason for equipment procurement determines application allocation. One scanner is not counted separately for every condition it can image; its neuroimaging-use revenue is assigned across mutually exclusive primary demand groups.
Neurological Disease Diagnosis represented an estimated ~42% of 2025 revenue. WHO reported more than three billion people living with neurological conditions in 2025, spanning dementia, epilepsy and degenerative disorders. MRI protocols reveal structural abnormalities, while PET supports selected specialist questions. Hospital investments are driven by diagnostic access and follow-up needs rather than population prevalence alone. High-field image quality, appointment capacity and neurologist availability shape the equipment choices.
Emergency CT is central to initial stroke and head injury assessment because time-sensitive decisions require rapid exclusion of hemorrhage. MRI may subsequently characterize ischemia and complex lesions, but fixed MRI is less accessible in many emergency departments. Samsung NeuroLogica markets the mobile CereTom head CT system, while Hyperfine offers portable MRI for selected bedside applications. This segment is particularly sensitive to emergency-care network design and transport delays.
Neurosurgeons and radiation oncologists use high-resolution MRI for lesion delineation, treatment planning and follow-up. Selected PET applications contribute molecular information when conventional anatomy is insufficient. The revenue boundary covers equipment used for brain tumors, not oncology drugs, surgery charges or radiotherapy machines. Demand is concentrated in tertiary hospitals where neuroradiology, pathology and multidisciplinary treatment teams are available.
Human neuroscience and translational centers purchase advanced MRI and molecular scanners for functional mapping, longitudinal cohorts and clinical trials. These installations often require specialized sequences, computing infrastructure and reproducibility across sites. Preclinical small-animal scanners are excluded from the clinical market boundary, even when marketed for neuroimaging research. Research demand can support premium hardware purchases, but grants and institutional capital cycles make revenue uneven.
Purchasing setting identifies the entity that acquires the imaging hardware: hospitals, independent diagnostic centers, or academic and specialty centers. The same scanner cannot be attributed to several buyers when examinations are referred from outside clinicians.
Hospitals represent the largest equipment purchasing channel because stroke units, neurology services and neurosurgery departments share MRI and CT resources. NHS England tracks imaging tests by provider, demonstrating the institutional scale of radiology operations. Tertiary hospitals may also maintain PET/MR or portable bedside imaging capacity. Capital committees evaluate service contracts, staffing and patient flow before procurement, which can delay purchase decisions despite strong clinical demand.
Freestanding diagnostic operators install MRI and CT systems to serve outpatient neurology referrals and follow-up studies. Throughput and operating cost are central because reimbursement is often tied to completed examinations. Philips and Siemens have emphasized workflow automation and helium-saving magnet designs, which can improve utilization. A center that purchases one multipurpose MRI is allocated only its brain-use portion, preventing inflation from unrelated musculoskeletal and abdominal imaging.
Academic medical centers and dedicated neurological facilities are early buyers of research-capable MRI, PET/MR and advanced image acquisition configurations. United Imaging obtained European CE marking for uPMR Zenith in 2026, providing a further hybrid platform for specialist use. Procurement can depend on grants, clinical trials and collaborative research agreements. This category excludes hospitals already classified under the main hospital buyer group, so facilities are assigned by their primary purchasing identity.
Hospitals should remain the principal source of capital demand, while outpatient centers may expand access through efficient scanner fleets. Academic institutions are more exposed to high-field and hybrid technology upgrades than routine community providers.
Imaging purpose classifies each acquisition by its primary output: anatomical structure, functional physiology, or molecular activity. The classification follows the dominant intended workflow rather than every optional sequence on the device.
Structural imaging is the principal purpose for routine brain CT and MRI, including hemorrhage assessment, mass localization and anatomical follow-up. Hospitals rely on rapid CT for emergencies and MRI for detailed tissue contrast. GE HealthCare and Siemens have introduced newer magnet systems designed to reduce operational friction. Equipment is assigned here when structural protocols dominate the clinical purchase rationale, even if a scanner also supports functional sequences.
Functional MRI and perfusion imaging examine blood flow, connectivity or task-related activation in selected neurological pathways. These workflows demand consistent acquisition protocols, specialist expertise and appropriate software integration. Portable systems can add selected bedside information but are not equivalent to high-field functional imaging. Revenue counts the acquisition hardware and included upgrades, excluding independent image interpretation or analytics subscriptions.
Molecular imaging uses PET tracers to characterize metabolism or selected neurological biomarkers, often combined with CT or MRI anatomy. United Imaging received CE marking for a PET/MR platform in September 2026, illustrating the investment required for integrated acquisition. Tracer costs and clinical scan charges remain outside the scanner revenue boundary. Specialist adoption depends on regulatory authorization, radiopharmacy logistics and reimbursement for the relevant clinical question.
Structural workflows remain the principal volume base, while functional and molecular applications can support premium equipment purchases in tertiary care and academic institutions.
Regional equipment revenue reflects imaging infrastructure, specialist staffing, scanner procurement cycles and the ability to support high-field MRI or PET systems. North America leads on value, while Asian manufacturers and Latin American public tenders expand the supplier landscape.
North America represented an estimated ~39% of global brain imaging device revenue in 2025. Large hospital networks, premium MRI configurations and specialist neuroradiology capacity support equipment spending. GE HealthCare received FDA clearances in February 2026 for new 1.5T and 3T MRI platforms, while Hyperfine has expanded portable brain imaging in the United States. Replacement purchasing remains linked to capital budgets and reimbursement rather than a simple count of neurological diagnoses. The Canadian market combines provincial purchasing with regional access challenges, making siting flexibility and service support material considerations for scanner selection.
GE HealthCare announced FDA 510(k) clearances on 19 February 2026 for SIGNA Sprint with Freelium, SIGNA Bolt and SIGNA One. These products address high-field imaging and workflow efficiency within a large installed scanner base. Hyperfine also obtained clearance for an Optive AI software update in August 2026, supporting selected portable neuroimaging. U.S. hospitals evaluate supported neurocritical-care protocols before adopting portable bedside MRI devices.
Source: GE HealthCare.
Hyperfine stated in 2025 that its Optive AI software was available for commercial use in Canada as well as the United States and selected other countries. Canadian buyers must still assess local device authorizations, reimbursement and staff training before purchasing portable MRI. Provincial capital funding and distances between specialist centers influence whether imaging is centralized or placed closer to acute-care patients.
Source: Hyperfine.
European neuroimaging equipment demand is supported by national health systems, university hospitals and established MRI manufacturers. Siemens Healthineers develops helium-saving MRI technology in Germany, while Philips introduced BlueSeal and SmartSpeed products for European radiology workflows. Hyperfine launched its next-generation Swoop in European markets in July 2026 following CE and UKCA approvals. Procurement is affected by public tender cycles, clinical staffing and local reimbursement for advanced neuroimaging. Specialized PET/MR investments are concentrated in facilities that can support molecular imaging expertise and tracer supply. German and British hospitals must also coordinate scanner procurement with radiographer staffing, regulatory compliance and long-term maintenance commitments.
Siemens Healthineers presented Magnetom Flow technology with a closed helium circuit, reducing coolant requirements to 0.7 liters. German hospital purchasers can evaluate such designs when renovation budgets and older MRI installations create replacement opportunities. High-field MRI remains important for brain tumor, epilepsy and neurodegenerative protocols, while procurement also depends on radiographer availability and service capacity.
Source: Siemens Healthineers.
NHS England reported 49.6 million imaging tests from April 2024 to March 2025 across all anatomical indications. CT and MRI activity contributes to a substantial public scanner workload, though those figures are not brain-only examinations. Hyperfine reported UKCA approval for its next-generation Swoop system in July 2026, adding a portable option for selected clinical settings.
Source: NHS England.
Asia-Pacific combines mature Japanese imaging manufacturers with expanding Chinese scanner development and large public healthcare networks. Fujifilm announced a zero-helium MRI system in April 2025, while Neusoft Medical presented advanced CT technology in China during the same year. Demand is heterogeneous: specialist centers purchase high-resolution MRI and PET configurations, whereas smaller hospitals often prioritize basic CT access and service coverage. The region benefits from domestic manufacturing but still faces shortages of trained imaging professionals in underserved areas. WHO highlights unequal access to neurological care across income groups, reinforcing the importance of operating cost and geographic deployment.
Neusoft Medical introduced the NeuViz Epoch Elite CT platform at a Chinese medical equipment exhibition in March 2025. Domestic scanner development can reduce reliance on imported systems and support regional service networks. Neuroimaging procurement remains tied to hospital capital budgets and local clinical requirements, so a general-purpose CT sale contributes only its brain-use allocation.
Source: Neusoft Medical.
Fujifilm announced the ECHELON Synergy ZeroHelium 1.5T MRI in April 2025 with a Japanese commercial launch planned for June. The design uses a wide bore and cooling architecture intended to reduce operating demands. Japanese hospitals have established MRI expertise, and replacement decisions increasingly compare energy use, patient comfort and scan efficiency alongside field strength.
Source: Fujifilm.
Latin American neuroimaging capacity is influenced by government purchasing, regional referral networks and differences between private and public hospital resources. Brazil issued a 2025 consultation for CT and MRI equipment specifications, while Mexico announced a 2026 acquisition of 17 MRI scanners. These are general imaging programs rather than dedicated brain-device orders, so revenue must be allocated to neuroimaging use. The opportunity is concentrated in replacing older equipment, improving emergency stroke access and shortening queues for neurological MRI. Financing and maintenance infrastructure can limit installations outside major metropolitan centers. Public hospital managers also need reliable service engineers and electricity infrastructure to translate new equipment tenders into sustained imaging access.
Brazil’s health ministry opened a July 2025 PAC +Imagem consultation covering a planned 40 CT and 40 MRI systems. Specifications included 64-channel CT and 1.5T MRI equipment for public healthcare procurement. These figures represent planned general radiology assets, not brain-only purchases, but they provide a concrete route for increasing neurological imaging capacity in underserved facilities.
Source: Brazil Ministry of Health.
The Mexican Social Security Institute announced 17 newly acquired MRI scanners in June 2026, including eleven 1.5T and six 3T systems. Officials described faster neurological examinations as a benefit of the modernization program. The acquisitions expand the general imaging fleet; brain-attributable equipment revenue is only the share supporting neuroimaging protocols and related capacity.
Source: IMSS.
Middle East and African imaging equipment demand varies sharply by health-system funding, specialist workforce and availability of advanced MRI maintenance. Major referral hospitals can procure high-field MRI and hybrid systems, while smaller facilities prioritize basic CT for emergency neurological care. WHO reported in October 2025 that low-income countries have far fewer neurologists than high-income countries, a constraint on effective scanner utilization. Investments in training, stable power and service contracts are therefore essential alongside hardware purchases. Portable MRI may support selected sites where transporting patients to centralized scanners is difficult, but clinical protocols and local approvals still determine use.
Large specialist hospitals in the United Arab Emirates can deploy MRI and CT for neurology, oncology and emergency pathways, while equipment procurement remains governed by local registration and hospital purchasing. Advanced PET/MR adoption requires tracer logistics and expert interpretation. Regional workforce shortages described by WHO make operator training and dependable service support commercially relevant to premium imaging installations.
Source: WHO.
Saudi tertiary-care facilities use advanced imaging within neurological and oncology referral pathways, with demand tied to hospital investment and the availability of trained specialists. Whole-body scanners serve many clinical departments, so neuroimaging revenue must be allocated by intended brain-use capacity rather than national disease burden. The WHO neurological-care assessment provides context for workforce planning and the need for accessible diagnostic services.
Source: WHO.
The competitive field spans multinational MRI and CT manufacturers, domestic Asian suppliers, and specialized portable brain imaging developers. Commercial positioning depends on installed service coverage, scanner uptime, clinical protocols and regulatory clearances rather than headline field strength alone.
SIGNA Bolt and Sprint gained U.S. FDA clearance in February 2026, expanding the company’s MRI choices for clinical departments.
Magnetom Flow.Ace received U.S. clearance in June 2025 and emphasizes lower helium requirements and workflow automation.
SmartSpeed Precise gained U.S. clearance in July 2025, while BlueSeal technology targets magnet siting and energy costs.
Vantage Fortian MRI and Aquilion CT platforms serve general imaging departments, with brain studies forming a portion of use.
ECHELON Synergy ZeroHelium was announced in April 2025 for a June Japanese launch, emphasizing operating efficiency.
Swoop portable MRI expanded in Europe in July 2026, followed by a new FDA-cleared Optive AI update in August.
uPMR Zenith obtained CE marking in September 2026, extending European molecular and structural imaging options.
NeuViz Epoch Elite and related CT offerings support high-resolution acquisition and domestic hospital procurement.
ScintCare BroadScan MRI and digital PET/CT platforms serve hospitals seeking broader scanner access and cost control.
CereTom is marketed for portable head CT in neurocritical care, where avoiding patient transfers can support bedside assessment.
Competition among GE HealthCare, Siemens Healthineers and Philips includes AI-assisted reconstruction, sealed magnets and scanner productivity. These features affect the total cost of ownership and can influence replacement timing in hospitals facing MRI waiting lists. Canon and Fujifilm offer additional MRI and CT alternatives, while Chinese manufacturers broaden the range of procurement choices. Ownership groups are counted once even where a brand operates through subsidiaries or distributors; unrelated ultrasound and radiography suppliers are not added merely to enlarge the company list.
Hyperfine focuses on portable brain MRI rather than matching every high-field protocol, and United Imaging competes through advanced hybrid platforms that require specialist infrastructure. Samsung NeuroLogica addresses mobile head CT applications in emergency and critical care. Supplier revenue from general-purpose imaging cannot be equated with the neuroimaging market because scanners also serve cardiology, oncology and musculoskeletal examinations. Local regulatory clearances, service contracts and hospital procurement determine which products can compete in each region.
September 2026: United Imaging Healthcare announced CE marking for uPMR Zenith PET/MR on 29 September 2026, enabling European market entry for its integrated molecular imaging platform. The system combines PET acquisition with magnetic resonance imaging and targets specialist workflows. Hospitals still require tracer supply and trained readers before neuroimaging applications can be deployed at scale. Source
August 2026: Hyperfine reported FDA clearance of an Optive AI software update on 20 August 2026 for its Swoop portable MRI system. The release added improved image quality and an isotropic imaging sequence. It expands capability within approved portable imaging workflows but does not make ultra-low-field MRI a substitute for every conventional 1.5T or 3T examination. Source
July 2026: Hyperfine began the European commercial launch of next-generation Swoop on 1 July 2026 after CE and UKCA approvals. Hyperfine initially distributed Swoop in European markets where established commercial partners could support clinical adoption. The portable system addresses selected bedside brain examinations and reduces reliance on patient transport, while local clinical protocols and training govern actual use. Source
February 2026: GE HealthCare received FDA 510(k) clearance for SIGNA Sprint with Freelium, SIGNA Bolt and SIGNA One on 19 February 2026. The systems combine new 1.5T and 3T MRI hardware with workflow software. Hospitals can evaluate the platforms for neuroimaging and other body applications, with only the brain-use share counted in this market. Source
July 2025: Philips announced FDA clearance for SmartSpeed Precise on 2 July 2025 across compatible 1.5T and 3T MRI systems. Philips reported faster MRI scanning and improved reconstruction clarity for supported SmartSpeed Precise workflows. These upgrades may increase throughput in neurological imaging departments and support equipment modernization, subject to approved software compatibility and clinical use. Source
June 2025: Siemens Healthineers reported FDA clearance for Magnetom Flow.Ace on 26 June 2025, introducing a 1.5T MRI platform with a closed helium circuit. The design reduces reliance on liquid helium and eliminates the quench pipe. The equipment can serve neurological protocols within a broader radiology workload, supporting replacement procurement where siting constraints matter. Source
The brain imaging device market is projected to increase from USD 12.3 billion in 2026 to USD 19.7 billion in 2034, corresponding to a 6.1% CAGR as hospitals renew scanner fleets and selected neurological imaging applications broaden.
| Forecast Variable | 2026 Starting Condition | Expected Effect Through 2034 |
|---|---|---|
| Neurological demand | More than 3B people affected worldwide | Sustains CT and MRI clinical capacity requirements |
| MRI technology | 1.5T and 3T sealed-magnet product launches | Reduces siting friction and supports upgrades |
| Portable scanners | Swoop European launch in July 2026 | Adds bedside use in selected settings |
| Public procurement | Brazil and Mexico equipment initiatives | Supports emerging-market installation cycles |
| Hybrid imaging | European CE mark for uPMR Zenith | Specialist molecular imaging investment |
| Workforce and budgets | Uneven access to trained specialists | Restrains conversion of clinical need into purchases |
MRI should retain the largest modality share because high-field imaging supports structural and selected functional neurological protocols. GE HealthCare, Siemens Healthineers and Philips are investing in reconstruction software, magnet efficiency and streamlined workflows that reduce operating friction. Hospitals can benefit through shorter appointment slots and better image consistency, but higher throughput on existing scanners can defer purchases where capacity is adequate. Revenue growth will therefore reflect replacement cycles and new installations rather than a direct one-for-one increase with examination volumes.
North America is expected to maintain value leadership through premium scanner installations, specialist hospital networks and established service infrastructure. European purchasing will remain shaped by public tenders and national approval pathways, while Asia-Pacific suppliers may increase competitive pressure through domestic CT and MRI manufacturing. Brazil and Mexico offer concrete examples of general radiology procurement initiatives, but their stated equipment counts must not be mistaken for brain-only scanner sales. The forecast includes only the neuroimaging-use allocation of these assets.
Portable imaging could widen access for critically ill patients who are difficult to transport to fixed scanners. Hyperfine’s 2026 European launch and software clearances provide an evidence-based commercialization route for selected bedside brain examinations. The segment faces limits from field strength, protocol coverage and hospital training requirements. Hybrid PET/MR systems address a different niche involving molecular information and advanced structural imaging; adoption depends on radiopharmacy support, specialist interpretation and the availability of clinical reimbursement.
The main downside risks are delayed hospital capital budgets, shortage of imaging technologists, site construction costs and inconsistent equipment servicing. Sealed magnets and AI reconstruction reduce some operating burdens but do not resolve every constraint. Demand may exceed the baseline where public systems fund stroke imaging networks, university hospitals install hybrid platforms and vendors offer economical upgrade packages. Equipment manufacturers with dependable maintenance and training programs are better positioned to convert announced procurement plans into recognized sales.
Coverage includes neuroimaging-use equipment revenue, four exclusive segment dimensions, regional purchasing patterns and manufacturer technology portfolios.
Worldwide brain-use-attributable imaging equipment revenue reached **USD 11.6 billion in 2025**. The figure covers MRI, CT, PET and hybrid scanner hardware allocated to neurological examinations, rather than the full value of multipurpose scanners or fees charged for individual patient scans.
The forecast implies a **6.1% CAGR from 2026 to 2034**, with revenue rising from USD 12.3 billion to USD 19.7 billion. Replacement of MRI fleets, scanner productivity upgrades and selected portable imaging deployments support growth, while staffing and capital costs restrain installation rates.
MRI Devices lead with an estimated **~48% of 2025 revenue**. Their premium capital value and utility for brain tumors, epilepsy and neurodegenerative conditions support the position. CT remains indispensable for acute stroke and trauma because emergency departments need rapid access to cross-sectional imaging.
CT is commonly used for rapid assessment of acute hemorrhage and trauma, while MRI provides detailed tissue contrast for many neurological and oncology protocols. CT or MRI selection depends on stroke urgency, magnetic-field contraindications and the specific neurological indication. Hospitals may need both technologies because neither modality replaces the other across all diagnostic tasks.
Hyperfine markets the Swoop portable MRI system for selected brain examinations and announced a European launch in July 2026 after CE and UKCA approvals. An additional FDA-cleared Optive AI update followed in August. Clinical indications and image quality differ from conventional high-field MRI, so hospitals must verify local authorization and protocols.
North America represented an estimated **~39% of global equipment revenue in 2025**. Premium MRI installations, specialist neuroimaging services and established maintenance networks contribute to its lead. European public purchasing and Asian scanner manufacturing provide important alternative growth channels through the forecast period.
GE HealthCare, Siemens Healthineers, Philips, Canon Medical and Fujifilm supply major MRI and CT platforms. Hyperfine specializes in portable brain MRI, United Imaging offers hybrid imaging systems, and Neusoft, MinFound and Samsung NeuroLogica provide additional clinical scanner options. MRI and CT product authorizations and manufacturer service coverage vary across national healthcare markets.
No. A combined PET/MR system is assigned to the hybrid device segment once, preventing double counting of its hardware value. Only the portion used for brain imaging is included when the scanner also serves other clinical indications. PET tracers, scan billing and independent interpretation services are excluded.
Neurological referrals, emergency capacity, scanner age and appointment queues influence hospital purchases. GE HealthCare gained FDA clearance for new SIGNA platforms in February 2026, while Philips and Siemens offer workflow and helium-saving innovations. Hospital budgets and available imaging technologists determine how quickly clinical need becomes a capital order.
Brazil consulted on planned procurement of 40 CT and 40 MRI systems in 2025, and Mexico announced 17 acquired MRI scanners in June 2026. Both initiatives concern general radiology fleets, not dedicated brain-only equipment. Their neurological benefit depends on installation sites, specialist staffing and access to maintenance.
High scanner purchase costs, site preparation, shortages of trained operators and maintenance obligations slow adoption. PET equipment adds radiotracer supply and specialist interpretation requirements. Helium-saving magnets and faster reconstruction can reduce operating burdens, but reimbursement and public procurement cycles still determine investment timing.
Advanced 1.5T and 3T MRI, portable low-field scanners and hybrid PET/MR platforms will serve different neurological pathways through 2034. The market is forecast to reach USD 19.7 billion as clinical demand and replacement spending expand. Technology uptake will depend on demonstrated workflow value and local regulatory approvals.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.